• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

准确可靠地预测大环化合物与其蛋白质靶标的结合亲和力。

Accurate and Reliable Prediction of the Binding Affinities of Macrocycles to Their Protein Targets.

机构信息

Schrodinger, Inc. , 120 West 45th Street, New York, New York 10036, United States.

出版信息

J Chem Theory Comput. 2017 Dec 12;13(12):6290-6300. doi: 10.1021/acs.jctc.7b00885. Epub 2017 Nov 30.

DOI:10.1021/acs.jctc.7b00885
PMID:29120625
Abstract

Macrocycles have been emerging as a very important drug class in the past few decades largely due to their expanded chemical diversity benefiting from advances in synthetic methods. Macrocyclization has been recognized as an effective way to restrict the conformational space of acyclic small molecule inhibitors with the hope of improving potency, selectivity, and metabolic stability. Because of their relatively larger size as compared to typical small molecule drugs and the complexity of the structures, efficient sampling of the accessible macrocycle conformational space and accurate prediction of their binding affinities to their target protein receptors poses a great challenge of central importance in computational macrocycle drug design. In this article, we present a novel method for relative binding free energy calculations between macrocycles with different ring sizes and between the macrocycles and their corresponding acyclic counterparts. We have applied the method to seven pharmaceutically interesting data sets taken from recent drug discovery projects including 33 macrocyclic ligands covering a diverse chemical space. The predicted binding free energies are in good agreement with experimental data with an overall root-mean-square error (RMSE) of 0.94 kcal/mol. This is to our knowledge the first time where the free energy of the macrocyclization of linear molecules has been directly calculated with rigorous physics-based free energy calculation methods, and we anticipate the outstanding accuracy demonstrated here across a broad range of target classes may have significant implications for macrocycle drug discovery.

摘要

大环化合物在过去几十年中作为一种非常重要的药物类别出现,主要是由于它们在合成方法上的进步,扩大了其化学多样性。大环化已被认为是一种有效的方法,可以限制无环小分子抑制剂的构象空间,从而提高其效力、选择性和代谢稳定性。由于大环化合物的尺寸相对较大,与典型的小分子药物相比,以及结构的复杂性,有效地采样可及的大环构象空间,并准确预测它们与靶蛋白受体的结合亲和力,在计算大环药物设计中具有重要意义。在本文中,我们提出了一种新的方法,用于计算不同环大小的大环化合物之间以及大环化合物与其相应的无环类似物之间的相对结合自由能。我们已经将该方法应用于七个来自最近药物发现项目的具有药物应用价值的数据集,其中包括 33 个大环配体,涵盖了多样化的化学空间。预测的结合自由能与实验数据吻合较好,整体均方根误差(RMSE)为 0.94kcal/mol。据我们所知,这是第一次使用严格的基于物理的自由能计算方法直接计算线性分子的环化自由能,我们预计这里展示的出色准确性可能对大环化合物药物发现具有重要意义。

相似文献

1
Accurate and Reliable Prediction of the Binding Affinities of Macrocycles to Their Protein Targets.准确可靠地预测大环化合物与其蛋白质靶标的结合亲和力。
J Chem Theory Comput. 2017 Dec 12;13(12):6290-6300. doi: 10.1021/acs.jctc.7b00885. Epub 2017 Nov 30.
2
In Silico Prediction of Ligand Binding Energies in Multiple Therapeutic Targets and Diverse Ligand Sets-A Case Study on BACE1, TYK2, HSP90, and PERK Proteins.基于多种治疗靶点和不同配体集的配体结合能的计算预测——以 BACE1、TYK2、HSP90 和 PERK 蛋白为例。
J Phys Chem B. 2017 Aug 31;121(34):8142-8148. doi: 10.1021/acs.jpcb.7b07224. Epub 2017 Aug 17.
3
Relative Binding Free Energy Calculations in Drug Discovery: Recent Advances and Practical Considerations.药物发现中的相对结合自由能计算:最新进展与实际考虑。
J Chem Inf Model. 2017 Dec 26;57(12):2911-2937. doi: 10.1021/acs.jcim.7b00564. Epub 2017 Dec 15.
4
Tackling the conformational sampling of larger flexible compounds and macrocycles in pharmacology and drug discovery.解决药物化学和药物发现中较大柔性化合物和大环的构象采样问题。
Bioorg Med Chem. 2013 Dec 15;21(24):7898-920. doi: 10.1016/j.bmc.2013.10.003. Epub 2013 Oct 16.
5
Conformational analysis of macrocycles: comparing general and specialized methods.大环的构象分析:比较通用方法和专用方法。
J Comput Aided Mol Des. 2020 Mar;34(3):231-252. doi: 10.1007/s10822-020-00277-2. Epub 2020 Jan 21.
6
Accurate and reliable prediction of relative ligand binding potency in prospective drug discovery by way of a modern free-energy calculation protocol and force field.通过现代自由能计算方案和力场,准确可靠地预测潜在药物发现中相对配体结合效力。
J Am Chem Soc. 2015 Feb 25;137(7):2695-703. doi: 10.1021/ja512751q. Epub 2015 Feb 12.
7
Structure-Based Macrocycle Design in Small-Molecule Drug Discovery and Simple Metrics To Identify Opportunities for Macrocyclization of Small-Molecule Ligands.基于结构的小分子药物发现中环状化合物设计及简单指标识别小分子配体环化机会
J Med Chem. 2019 Aug 8;62(15):6843-6853. doi: 10.1021/acs.jmedchem.8b01985. Epub 2019 Mar 22.
8
Accurate Calculation of Relative Binding Free Energies between Ligands with Different Net Charges.不同净电荷配体之间相对结合自由能的精确计算
J Chem Theory Comput. 2018 Dec 11;14(12):6346-6358. doi: 10.1021/acs.jctc.8b00825. Epub 2018 Nov 12.
9
Protein-Ligand Binding Free Energy Calculations with FEP.使用自由能微扰法进行蛋白质-配体结合自由能计算
Methods Mol Biol. 2019;2022:201-232. doi: 10.1007/978-1-4939-9608-7_9.
10
Accurate Modeling of Scaffold Hopping Transformations in Drug Discovery.准确建模药物发现中的支架跳跃转化。
J Chem Theory Comput. 2017 Jan 10;13(1):42-54. doi: 10.1021/acs.jctc.6b00991. Epub 2016 Dec 9.

引用本文的文献

1
Exploring Macrocyclic Chemical Space: Strategies and Technologies for Drug Discovery.探索大环化学空间:药物发现的策略与技术
Pharmaceuticals (Basel). 2025 Apr 24;18(5):617. doi: 10.3390/ph18050617.
2
Computational analysis of lupenone derivatives as potential inhibitor of human papillomavirus oncoprotein E6 associated cervical cancer.羽扇豆酮衍生物作为人乳头瘤病毒癌蛋白E6相关宫颈癌潜在抑制剂的计算分析
Sci Rep. 2025 May 2;15(1):15402. doi: 10.1038/s41598-025-96667-3.
3
Zidesamtinib Selective Targeting of Diverse ROS1 Drug-Resistant Mutations.
齐德替尼对多种ROS1耐药突变的选择性靶向作用。
Mol Cancer Ther. 2025 Jul 2;24(7):1005-1019. doi: 10.1158/1535-7163.MCT-25-0025.
4
Konnektor: A Framework for Using Graph Theory to Plan Networks for Free Energy Calculations.连接器:使用图论规划自由能计算网络的框架。
J Chem Inf Model. 2024 Nov 25;64(22):8396-8403. doi: 10.1021/acs.jcim.4c01710. Epub 2024 Nov 5.
5
Selection pressures on evolution of ribonuclease H explored with rigorous free-energy-based design.利用严格的基于自由能的设计探索核糖核酸酶 H 进化的选择压力。
Proc Natl Acad Sci U S A. 2024 Jan 16;121(3):e2312029121. doi: 10.1073/pnas.2312029121. Epub 2024 Jan 9.
6
The maximal and current accuracy of rigorous protein-ligand binding free energy calculations.严格的蛋白质-配体结合自由能计算的最大及当前精度。
Commun Chem. 2023 Oct 14;6(1):222. doi: 10.1038/s42004-023-01019-9.
7
An Intriguing Purview on the Design of Macrocyclic Inhibitors for Unexplored Protein Kinases through Their Binding Site Comparison.通过结合位点比较对未探索蛋白激酶大环抑制剂设计的有趣审视
Pharmaceuticals (Basel). 2023 Jul 17;16(7):1009. doi: 10.3390/ph16071009.
8
PptT Inhibitors Based on Heterocyclic Replacements of Amidinoureas.基于脒基脲杂环取代物的PptT抑制剂。
ACS Med Chem Lett. 2023 Jun 26;14(7):970-976. doi: 10.1021/acsmedchemlett.3c00162. eCollection 2023 Jul 13.
9
NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations.NVL-520 是一种选择性、TRK 规避、脑穿透的 ROS1 融合和继发耐药突变抑制剂。
Cancer Discov. 2023 Mar 1;13(3):598-615. doi: 10.1158/2159-8290.CD-22-0968.
10
Best practices for constructing, preparing, and evaluating protein-ligand binding affinity benchmarks [Article v0.1].构建、准备和评估蛋白质-配体结合亲和力基准的最佳实践[文章v0.1]
Living J Comput Mol Sci. 2022;4(1). doi: 10.33011/livecoms.4.1.1497. Epub 2022 Aug 30.